Minnesota health maintenance organizations increased their average per-member premium revenue but continued to lose money, according to the recently released Minnesota Managed Care Review 1999.
Minnesota health maintenance organizations increased their average per-member premium revenue but continued to lose money, according to the recently released Minnesota Managed Care Review 1999. The review, the tenth annual report assessing the Minnesota health care market, is a competitive analysis of health plans in the state.
The study found that:
•Â HMOs' premium revenues for commercial (employer) plans increased by an average of 9.9%.
•Â Despite those increases, Minnesota HMOs lost $9.6 million, or 0.3% of $2.9 billion in revenues in 1998.
•Â HMOs increased profits on their Medicaid plans from $25.9 million in 1997 to $33.8 million in 1998.
•Â Enrollment in insured HMO plans declined by about 45,000 in 1998.
According to Allan Baumgarten, the independent research analyst and health care policy and finance consultant who authored the report, the findings of the study may also reveal national trends. "In Minnesota and a number of other markets, we're seeing some large employer groups going not from preferred provider organizations to HMOs, which was sort of the conventional wisdom, but, in fact, going the opposite direction â from HMOs back to PPOs, something more lightly managed," he said.
To counter the loss of membership that this employer-driven shift would bring, Baumgarten said HMOs will start diversifying into other products: "You'll see more HMOs wanting to perhaps add these lines of business â PPOs and other more lightly managed care â so if they have unhappy customers, they can say, 'Wait a minute, we have other products in our line⦠that maybe address some of your concerns.'"
The problem with this diversification, however, is that HMOs may not have the right skill sets to offer other types of managed care products. "That might be one of the factors that distinguishes the companies that are going to be successful⦠and [the ones] that are going to have serious problems," Baumgarten said.
The results of the study reveal a cloudy horizon for HMOs. "HMOs are still under a lot of pressure both on the profitability, premium and medical cost side," Baumgarten said. "Plus, customers are raising questions about the value they get from their HMOs. It all adds up to a very challenging time for HMOs." PR
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.